NMA reveals superior CST improvement of Vabysmo over Eylea HD

A match-adjusted meta-analysis indirectly comparing the efficacy of Eylea HD ( aflibercept 8mg) and Vabysmo (faricimab). presented by Dr. Jennifer I Lim, MD, FARVO, FASRS, the Marion Schenk Chair in Ophthalmology for Aging Eye Research and Distinguished Professor of Ophthalmology at the University of Illinois at Chicago.

Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor, available in a 2 mg dose as Eylea and in an 8 mg dose as Eylea HD. Vabysmo (faricimab) is a dual inhibitor of VEGF and angiopoietin-2 (Ang-2). Both therapies are indicated for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), among other diseases. Although numerous studies have investigated both therapies individually, to date there have been no trials directly comparing the two therapies.

This study aimed to compare 12-week data from relevant phase III trials for Eylea HD and Vabysmo, with the aim of unraveling which treatment provided superior reductions in central subfield thickness (CST). This was achieved by comparing data from the DME YOSEMITE/RHINE trials with PHOTON and the nAMD TENAYA/LUCERNE trials with PULSAR. All trials within the respective sub-indications had a common comparator, Eylea, which served as the anchor in this study, to facilitate the comparison between Eylea HD and Vabysmo. The trial duration was set at 12 weeks to ensure that patients in all trials used in the network meta-analysis (NMA) received the same number of injections, either Eylea, Eylea HD or Vabysmo.

After selecting the relevant clinical trials to conduct the NMA, the YOSEMITE/RHINE trial populations, comparing Eylea with Vabysmo in patients with DME, were compared with the baseline characteristics of the PHOTON trial, comparing Eylea with Eylea HD in patients with DME. The comparison was carried out based on characteristics such as mean age, average best-corrected visual acuity (BCVA), diabetic retinopathy severity scale (DRSS) absent, mild or moderate and, in particular, average CST, previous treatment with anti-VEGF and moderately severe or severe. Severe DRSS, characteristics that had a greater difference at baseline between the PHOTON and YOSEMITE/RHINE trials. This was done by applying weights and the YOSEMITE/RHINE results were modified accordingly.

Results revealed that in patients with DME, Vabysmo provided greater CST reduction compared to Eylea HD, with Vabysmo CST thinning 19 µm more than Eylea and Eylea HD from baseline to at week 12, showing that Vabysmo dries better than Eylea and Eylea HD.

This analysis was then performed on the respective nAMD data. Data from TENAYA/LUCERNE, which compared Eylea with Vabysmo in patients with nAMD, were compared with the baseline characteristics of the PULSAR trial, which compared Eylea with Eylea HD in patients with nAMD. In this case, the comparison was carried out on characteristics that included mean age, mean BCVA, mean CST, and mainly the percentage of absence of intraretinal fluid or subretinal fluid and characteristics of the lesion area mean that they had a larger difference at baseline between PULSAR and TENAYA/LUCERNE. essays In this analysis, the results obtained from the DME trial were further established, again demonstrating a higher CST reduction with Vabysmo than Eylea HD, with Vabysmo CST thinning of 19 µm more than Eylea and 17 µm more than Eylea HD from baseline to week 12, confirming that Vabysmo dries better than Eylea and Eylea HD.

Key opinion leaders (KOLs) interviewed by GlobalData highlighted the lack of data directly comparing Eylea HD with Vabysmo, expressing that it would be difficult to evaluate the two therapies due to differences in inclusion and exclusion criteria between their respective essays. However, this NMA serves as a way to bridge the gap between trials for both therapies and provide an indication of how these therapies compare to each other based on existing data.

Although these data serve as a testament to the superior improvements of Vabysmo in CST over Eylea HD in both DME and AMD, it is worth noting that this study was not without limitations; data from the PHOTON and PULSAR trials did not consider individual patient data and were pooled. In addition, there may have been influential differences in other characteristics that were not accounted for in the study. However, Vabysmo’s superior CST enhancements further fuel interest in its characteristic dual pathway inhibition.

According to GlobalData’s Pharma Intelligence Center, for DME, worldwide, there are 15 Phase III candidates, 32 Phase II candidates, and eight Phase I candidates. For wet AMD, worldwide world, there are 30 phase III candidates, 36 phase II candidates and 15 phase I candidates.

“AAO 2024: NMA Reveals Superior CST Improvement of Vabysmo over Eylea HD” was originally created and published by Pharmaceutical Technology, a brand owned by GlobalData.

The information on this site has been included in good faith for general informational purposes only. It is not intended to be advice on which you should rely, and we make no representations, warranties or guarantees, either express or implied, as to its accuracy or completeness. You should obtain professional or specialist advice before taking or refraining from any action based on the content of our site.

Related Posts

Sify Technologies has found Padmaja Chunduru in the Investing.com database

Sonos Sub 4 and Sonos Sub 3 with Vegleich: Wie viel besser is der new subwoofer?

Drew Barrymore removes her hair extensions live on TV as she reveals a symptom of perimenopause